FiercePharma2h
Gilead supports creation of ‘sanctuary’ resource hub for Black triple-negative breast cancer patients
Triple-negative breast cancer, or TNBC, is a rare and especially aggressive form of breast cancer that grows and spreads ...
FiercePharma2h
Johnson & Johnson, Merck lay off workers in China as local headwinds take a toll
Johnson & Johnson and Merck are laying off workers in China, according to a story from Bloomberg which cites reports from ...
FiercePharma3h
Rapid growth spurt for UCB's Bimzelx continues with hidradenitis suppurativa nod marking 5th FDA approval
It was only last October that UCB’s up-and-coming immunology powerhouse Bimzelx first crossed the FDA finish line in ...
FiercePharma3h
Plasma specialist Grifols shrugs off private equity firm Brookfield's potential €6.5B takeover offer
With Spanish plasma specialist Grifols turning down a potential multi-billion-dollar takeover bid, it’s likely back to the ...
FiercePharma4h
Roche files patent suit to fend off potential Evrysdi generics from Zydus, Natco
Roche's spinal muscular atrophy (SMA) medicine Evrysdi only gained its FDA approval in 2020, but generics companies are ...
FiercePharma4h
PCI and ChiRhoClin partner to prevent shortage of pancreatic diagnostic drug
PCI Pharma Services, a CDMO, and the biotech ChiRhoClin inked a collaboration deal to address the potential shortage of a ...
FiercePharma4h
FDA slams Indian drugmaker Unexo with warning letter for 'significant violations'
Unexo Life Sciences, an Indian drugmaker that manufactures a medicated patch for pain relief, has been hit with a ...
FiercePharma5h
AstraZeneca to go on defense for Andexxa as FDA questions bleeding reversal agent's safety ahead of adcomm
As a council of outside experts prepares to meet Thursday to discuss AstraZeneca’s Andexxa, the FDA has flagged “major safety ...